Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe

News Update


Biopharma Recaps 2020 Accomplishments in COVID-19, Idiopathic Pulmonary Disease
News Update

Share on Stocktwits


Algernon Pharmaceuticals reports that it is aggressively advancing its repurposed drug, Ifenprodil.

Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW:FSE) summarized in a news release its primary clinical and corporate activities of 2020.

As for its COVID-19 clinical research program, the company filed for and received approval of its investigational new drug application from the U.S. Food and Drug Administration for a multinational Phase 2b/3 COVID-19 study of Ifenprodil. Patient enrollment began in early August and was completed by November's end. On Dec. 15, 2020, Algernon "reported, in a descriptive format, positive trending interim data for the Phase 2b part of the Company's Ifenprodil COVID-19 study." Subsequently, on Dec. 24, it announced that the last trial patient was treated and reached the end of the required two-week follow-up period.

In addition, the first patient of Algernon's Phase 2, multisite study of Ifenprodil in idiopathic pulmonary fibrosis and chronic cough was dosed in August in New Zealand, and trial enrollment as of Oct. 15, 2020, was at 25%. The study is ongoing, at three Australia and two New Zealand sites.

"While we have made significant progress this past year aggressively advancing our repurposed drug compound Ifenprodil, by initiating two Phase 2 clinical trials and accomplishing additional related goals and milestones, we are planning for an even more active 2021," CEO Christopher J. Moreau said in the release.

With respect to finances, Algernon most recently, in November, received a refundable CA$600,000 tax credit from its clinical research work in Australia. This covered 40% of allowable expenses refunded from the company's clinical trial.

Earlier, in May, Algernon "closed a private placement offering of special warrants of the Company and issued 19,605,285 warrants at a price of CDN$0.35 each, for aggregate gross proceeds of approximately CDN$6,861,849.00 (the Company filed a prospectus shortly thereafter to qualify the 19,605,285 special warrants issued, with each special warrant converted into one common share and one common share purchase warrant at $CDN.55)." In February, the biopharma closed a nonbrokered private placement in which it issued 18,304,939 units and raised CA$1,555,919 in gross proceeds. "Each Unit was comprised of one Class A common share (a "Share") and one Share purchase warrant. Each whole warrant will entitle the holder to acquire one additional Share at a price of CDN$0.12 per Share," the company reported.

During 2020, Algernon appointed Dr. Jacky Smith and Dr. Mark Swaim to its Medical and Scientific Advisory Board, Howard Gutman to its newly created Business Advisory Board, and CEO Moreau to its board of directors.


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Algernon Pharmaceuticals. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Algernon Pharmaceuticals, a company mentioned in this article.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe